In favour of a Millian proposal to reform biomedical research

Synthese

Volumn 177, Issue 3, 2010, Pages 427-447

  Reiss, Julian ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Biomedical research; Global Justice; John Stuart Mill; Methodology

Indexed keywords

EID: 78650214800     PISSN: 00397857     EISSN: 15730964     Source Type: Journal    
DOI: 10.1007/s11229-010-9790-7     Document Type: Article

References (69)

1. Aaron H. (2003) The costs of health care administration in the United States and Canada-questionable answers to a questionable question. New England Journal of Medicine 349(8): 801-803.
2. Adam M. (2008) Promoting disinterestedness or making use of bias? Interests and moral obligation in commercialized research. In: Carrier M., Howard D., Kourany J. (eds) The challenge of the social and the pressure of practice: Science and values revisited. Pittsburgh University Press, Pittsburgh, PA, pp 235-255.
3. Als-Nielsen B., Chen W., Gluud C., Kjaergard L. (2003) Association of funding and conclusion in randomized drug trials: A reflection of treatment effect of adverse events?. Journal of the American Medical Association 290(7): 921-928.
4. Angell M. (2004) The truth about the drug companies. Random House, New York, NY.
5. Anuradha, R. V. (2001, May 20). Biopiracy and traditional knowledge. The Hindu.
6. Bekelman J., Li Y., Gross C. (2003) Scope and impact of financial conflicts of interest in biomedical research. Journal of the American Medical Association 289(4): 454-465.
7. Biddle J. (2007) Lessons from the Vioxx debacle: What the privatization of science can teach us about social epistemology. Social Epistemology 21: 21-39.
8. Blumenthal D., Campbell E., Anderson M., Causino N., Louis K. (1997) Withholding research results in academic life science. Journal of the American Medical Association 277(15): 1224-1228.
9. Bodenheimer T. (2000) Uneasy alliance. New England Journal of Medicine 342(20): 1539-1544.
10. Boldrin, M., & Levine, D. (2002). Perfectly competitive innovation. Research Department Staff Report 303. Minneapolis, MN.
11. Boldrin M., Levine D. (2008) Against intellectual monopoly. Cambridge University Press, Cambridge.
12. Brown J. R. (2002) Funding, objectivity and the socialization of medical research. Science and Engineering Ethics 8: 295-308.
13. Brown J. R. (2004) Money, method, and medical research. Episteme 1: 49-59.
14. Brown, J. R. (2006). Regulation and research: Approaches to market failures in medicine. In Commerce, politics and science conference, Notre Dame.
15. ®. In: Carrier M., Howard D., Kourany J. (eds) The challenge of the social and the pressure of practice: Science and values revisited. Pittsburgh University Press, Pittsburgh, PA, pp 189-216.
16. Campbell E., Gruen R., Mountford J., Miller L., Cleary P., Blumenthal D. (2007) A national survey of physician-industry relationships. New England Journal of Medicine 356(17): 1742-1750.
17. Carrier M. (2008) Science in the grip of the economy: On the epistemic impact of the commercialization of research. In: Carrier M., Kourany J., Howard D. (eds) The challenge of the social and the pressure of practice: Science and values revisited. University of Pittsburgh Press, Pittsburgh, PA, pp 217-234.
18. Cartwright N. (2006) Well-ordered science: Evidence for use. Philosophy of Science 73: 981-990.
19. Cartwright N. (2007) Are RCTs the gold standard?. BioSocieties 2(2): 11-20.
20. Chalmers I. (1990) Underreporting research is scientific misconduct. Journal of the American Medical Association 263(10): 1405-1408.
21. Chin, T. (2002, May 6). Drug firms score by paying doctors for time. American Medical News.
22. Chow S.-C., Liu J.-P. (2002) Design and analysis of clinical trials: Concepts and methodologies (2nd ed.). Wiley, Hoboken, NJ.
23. Christensen J., Orlowski J. (2005) Bounty-hunting and finder's fees. IRB: Ethics & Human Research 27(3): 16-19.
24. Cohen J., Gürtler R. (2001) Modeling household transmission of American trypanosomiasis. Science 293: 694-698.
25. De Francisco, A., & Matlin, S. (2006). Monitoring financial flows for health research 2006: The changing landscape of health research for development. Geneva: Global Forum for Health Research.
26. Donohue J., Cevasco M., Rosenthal N. (2007) A decade of direct-to-consumer advertising of prescription drugs. New England Journal of Medicine 357: 673-681.
27. Getz K. (1999) AMCs rekindling clinical research partnerships with industry. Centerwatch, Boston.
28. Global Forum for Health Research. (2004a). The 10/90 report on health research 2003-2004. Geneva: Global Forum for Health Research.
29. Global Forum for Health Research. (2004b). Monitoring financial flows for health research (Vol. 2). Geneva: Global Forum for Health Research.
30. Harris, G. (2004, December 6). At F. D. A., strong drug ties and less monitoring. New York Times.
31. Hartman, M., Martin, A., McDonnell, P., Catlin, A., & the National Health Expenditure Accounts Team. (2009). National health spending in 2007: Slower drug spending contributes to lowest rate of overall growth since 1998. Health Affairs, 28(1), 246-261.
32. Heffner, S. (2004, March). Beyond the CRO. Contract Pharma.
33. Hilts P. (2003) Protecting America's health: The FDA, business, and one hundred years of regulation. University of North Carolina Press, Chapel Hill, NC.
34. Hollis A., Pogge T. (2008) The health impact fund: Making new medicines accessible for all. New Haven, CT, Incentives for Global Health.
35. Howson C., Urbach P. (2005) Scientific reasoning: The Bayesian approach. Open Court, Chicago and LaSalle, IL.
36. Kaiser Family Foundation. (2008). Prescription drug trends. Menlo Park, CA: Kaiser Family Foundation.
37. Kincaid H. (2004) Contextualism, explanation and the social sciences. Philosophical Explorations 7(3): 201-218.
38. Kincaid, H., Dupré, J., Wylie, A. (eds) (2007) Value-free science? Ideals and illusions. Cambridge University Press, Cambridge.
39. Kincaid, H., McKitrick, J. (eds) (2007) Establishing medical reality: Essays on the metaphysics and epistemology of science. Springer, Heidelberg.
40. Kitcher P. (1993) The advancement of science. Oxford University Press, Oxford.
41. Kitcher P. (2001) Science, truth and democracy. OUP, Oxford.
42. Kreling, D., Mott, D., Wiederholt, J., Lundy, J., & Levitt, L. (2001). Prescription drug trends: A chartbook update. Menlo Park, CA: Kaiser Family Foundation.
43. Krimsky S. (2003) Science in the private interest: Has the lure of profits corrupted biomedical research?. Rowman & Littlefield, Lanham, MD.
44. Longino H. (1990) Science as social knowledge. Princeton Universty Press, Princeton, PA.
45. Longino H. (2002) The fate of knowledge. Princeton Universty Press, Princeton, PA.
46. Mayo D. (1996) Error and the growth of experimental knowledge. University Press, Chicago IL.
47. McGoey, L., Reiss, J., & Wahlberg, A. (forthcoming). The health complex: Progress and pathologies in global health funding and governance. BioSocieties.
48. Mirowski P., Sent E.-M. (2002) Introduction, Science bought and sold: Essays in the economics of science. University of Chicago Press, Chicago IL.
49. Mirowski P., van Horn R. (2005) The contract research organization and the commercialization of scientific research. Social Studies of Science 34(4): 503-548.
50. Mitchell S. (2009) Unsimple truths. University of Chicago Press, Chicago, IL.
51. Morgan S., Raymond C., Mooney D., Martin D. (2008) The Canadian RX atlas (2nd ed.). Centre for Health Services and Policy Research, Vancouver, BC.
52. Moynihan R. (2003) Who pays for the pizza? Redefining the relationships between doctors and drug companies. British Medical Journal 326: 1189-1196.
53. Pogge T. (2005) Human rights and global health: A research program. Metaphilosophy 36(1/2): 182-209.
54. Pollack, A. (2001, January 8). Bristol-Myers and Athersys make deal on gene patents. New York Times.
55. Public Citizen. (2001). Rx R& D myths: The case against the drug industry's R& D "scare card". Washington, DC: Public Citizen.
56. Public Citizen. (2003). 2002 Drug industry profits: Hefty pharmaceutical company margins dwarf other industries. Washington, DC: Public Citizen.
57. Public Library of Science. (2006). Special issue on disease mongering. PLoS Medicine, 3(4).
58. Putnam H. (2002) The fact/value dichotomy and other essays. Harvard University Press, Cambridge, MA.
59. Reiss J., Kitcher P. (2009) Biomedical research, neglected diseases and well-ordered science. Theoria 24(3): 263-282.
60. Risse, M. (forthcoming). The grounds of justice. Princeton, NJ: Princeton University Press.
61. Rosenthal M., Bernt E., Donohue J., Frank R., Epstein A. (2002) Promotion of prescription drugs to consumers. New England Journal of Medicine 346(7): 498-505.
62. Selgelid M. (2005) Ethics and infectious disease. Bioethics 19(3): 272-289.
63. Shuchman M. (2007) Commercializing clinical trials-risks and benefits of the CRO boom. New England Journal of Medicine 357(14): 1365-1368.
64. Stiglitz J. (2006a) Making globalization work. Norton, New York, NY.
65. Stiglitz J. (2006b) Scrooge and intellectual property rights: A medical prize fund could improve the financing of drug innovations. British Medical Journal 333: 1279-1280.
66. Wilholt T. (2006) Design rules: Industrial research and epistemic merit. Philosophy of Science 73(1): 66-89.
67. Wilkes M., Bell R., Kravitz R. (2000) Direct-to-consumer prescription durg advertising: Trends, impact, and implications. Health Affairs 19(2): 110-128.
68. Woolhandler S., Campbell T., Himmelstein D. (2003) Costs of health care administration in the United States and Canada. New England Journal of Medicine 349: 768-775.
69. Worrall J. (2002) What evidence in evidence-based medicine. Philosophy of Science 69: S316-S330.